


IN THE CLAIMS:

In accordance with the allowed format of amendments, each claim of record is mentioned or appears set forth below. Please replace all prior versions of the pending claims with the version that follows.

For the Examiner's convenience, claims 1-23 and 28-38 are pending, claims 3 and 9 are withdrawn, and claims 30-38 are new. Applicants currently amend claims 1, 22, 23, 28, and 29 to correct a typographical error in formula VII.

1. (Currently amended) A composition comprising:

- a) at least one physiologically tolerated film-forming agent;
- b) at least one physiologically tolerated solvent;
- c) at least one plasticizer; and
- d) a compound of the formula I



or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

- R¹ is
- 1) -CN,
 - 2) -NO₂,

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

3) a halogen, or

4) (C₁-C₄)-alkyl-C(O)-OH;

R² is

1) -CF₃,

2) a halogen, or

3) -CN;

R³ is


1) =O,

2) =S, or

3) =NH;


X is

1) a radical of formula II



or


2) a radical of formula III



or X and Y together form a group of formula IV

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com




- in which R⁴ is
- 1) hydrogen atom,
 - 2) (C₁-C₆)-alkyl-,
 - 3) (C₂-C₆)-alkenyl-, or
 - 4) (C₁-C₆)-alkyl-,

wherein the alkyl is mono- to trisubstituted by

- 4.1 -OH,
- 4.2 halogens,
- 4.3 -O-(C₁-C₄)-alkyl,
- 4.4 -CN, or
- 4.5 -SH;

- Y is 1) a radical of formula V



in which:


FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

R^5 is, independently of R^6 , a hydrogen atom or (C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono- to tetrasubstituted by halogens, and R^6 is, independently of R^5 , (C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by

- a) halogens,
- b) phenyl-(CH₂)_m-, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by -COOH, -CN, or -CF₃, and m is the integer zero, 1, 2, 3, 4, 5, or 6,
- c) -COOH,
- d) -CN, or
- e) -CF₃, or

2) radical of formula VI,




in which R^4 is as defined above; and

- Z is 1) -O- or
- 2) a radical of formula VII

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com



wherein said compound of formula I is released from the film formed by application of said composition to a skin surface.

2. (Original) A composition as claimed in claim 1, wherein the compound of formula I is a compound in which:

- R¹ is 1) -CN,
2) -NO₂, or
3) a halogen;

- R² is 1) -CF₃ or
2) a halogen;

- R³ is 1) =O or
2) =S;

X is the radical of formula II or III, or

X and Y together form the group of formula IV,

in which R⁴ is as defined in claim 1;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Y is the radical of formula VI,

in which R^4 is as defined in claim 1; and

Z is the radical of formula VII.

3. (Withdrawn) A composition as claimed in claim 1, wherein the compound of formula I is a compound in which:

R^1 is -CN;

R^2 is -CF₃;

R^3 is =O;

X is the radical of formula II;

Y is the radical of formula VI, in which R^4 is hydrogen; and

Z is -O- or the radical of formula VII.

4. (Original) A composition as claimed in claim 1, wherein the compound of formula I is chosen from 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)benzonitrile and 4-(5-methyl-2,4-dioxo-5-trifluoromethyl)-oxazolidin-3-yl)-2-(trifluoromethyl)-benzonitrile.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

5. (Original) A composition as claimed in claim 1, wherein the at least one plasticizer is chosen from ethoxylated compounds, panthenol, esters of adipic acid, and esters of sebacic acid.
6. (Original) A composition as claimed in claim 5, wherein the at least one plasticizer is chosen from polyoxyethylated castor oil, ethoxylated cholesterol, and panthenol.
7. (Original) A composition as claimed in claim 1, wherein the at least one physiologically tolerated solvent is chosen from water and (C₁-C₆)-alcohols.
8. (Original) A composition as claimed in claim 7, wherein the (C₁-C₆)-alcohols are chosen from methanol, ethanol, propanol, isopropanol, butanol, pentanol, and hexanol.
9. (Withdrawn) A composition as claimed in claim 1, wherein the at least one physiologically tolerated film-forming agent comprises at least one naturally occurring substance chosen from alginic acid, alginates, collagen, collagen derivatives, hydrolyzed wheat proteins, carrageenan, cellulose, cellulose derivatives, chitosan, chitosan derivatives, keratin hydrolysates, protein hydrolysates, gelatin, guar gum, guar gum derivatives, hydrolyzed elastin, hydrolyzed milk proteins, hydrolyzed silk proteins, hydrolyzed soya proteins, hydrolyzed oat proteins, copolymers of hydroxyethylcellulose, dimethyldiallylammonium chloride, hyaluronic acid, hyaluronates, tragacanth, and xanthan.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

10. (Original) A composition as claimed in claim 1, wherein the at least one physiologically tolerated film-forming agent comprises at least one synthetic substance chosen from acrylate/acrylamide copolymers, acrylate copolymers, acrylate/octylacrylamide copolymers, acrylic acid ester copolymers, methacrylic acid copolymers, adipic acid/dimethyl-aminohydroxypropyldiethylenetriamine copolymers, methacrylic acid/methacrylic acid ester copolymers neutralized with 2-amino-2-methylpropanol, polyacrylic acid crosslinked with pentaerythritol ethers or sugar allyl ethers, polysiloxane/polyalkyl polyether copolymers, polysiloxanes, ethylene/acrylic acid ester copolymers, ethylene/vinyl acetate copolymers, methacryloylethylbetaine/methacrylic acid copolymers, octylacrylamide/acrylic acid ester/butylaminoethylmethacrylic acid copolymers, quaternized polyvinylpyrrolidone-dimethylaminoethylmethacrylic acid esters, polyvinylpyrrolidone/imidazolium methochloride copolymers, sodium acrylate/dimethyldiallylammonium chloride copolymers, dimethyldiallylammonium chloride/sodium acrylate/acrylamide terpolymers, poly(dimethylsiloxane-copolyol-phospho-panthenoate), poly(methyl vinyl ether-maleic anhydride), poly(methyl vinyl ether-maleic acid monoalkyl ester), poly(vinylpyrrolidone), terpolymers based on pyrrolidone and acrylic acid compounds, poly(vinylpyrrolidone-dimethylaminoethylmethacrylic acid), polyvinylpyrrolidone/eicosene copolymers, polyvinylpyrrolidone/methacrylic acid ester/methacrylic acid terpolymers, polyvinylpyrrolidone/hexadecene copolymers, polyvinylpyrrolidone/polycarbamyl polyglycol ester, polyvinylpyrrolidone/vinyl acetate copolymers, vinylimidazolium methochloride/vinylpyrrolidone copolymers, acrylic acid/acrylic acid ester copolymers and terpolymers of vinyl pyrrolidone, vinyl acetate, and vinyl propionate.

C
cont'd

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

11. (Original) A composition as claimed in claim 1, further comprising at least one additive chosen from circulation-promoting compounds, angiotensin converting enzyme inhibitors, methylxanthine compounds, sodium channel openers, and hair growth-promoting compounds.

12. (Original) A composition as claimed in claim 11, wherein at least one circulation-promoting compound is chosen from dihydralazine, diisopropylamine, diazoxide, and calcium antagonists.

13. (Original) A composition as claimed in claim 12, wherein at least one calcium antagonist is chosen from nifedipine, nicardipine, verapamil, diltiazem, nisoldipine, nitrendipine, nivaldipine, isradipine, felodipine, nimodipine, gallopamil, fendiline, flunarizine, amlodipine, doperdipine, fluspirilene, primozide, fantofarone, nicergoline, cyclandelate, and 6-amino-4-piperidino-1,2-dihydro-1-hydroxy-2-iminopyrimidine.

14. (Original) A composition as claimed in claim 11, wherein at least one angiotensin converting enzyme inhibitor is chosen from quinapril, lisinopril, benzazepril, captopril, ramipril, fosinopril, cifazapril, and tradolapril.

15. (Original) A composition as claimed in claim 11, wherein at least one methylxanthine compound is chosen from pentoxifyllin, propentofyllin, and torbafyllin.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com


16. (Original) A composition as claimed in claim 11, wherein at least one sodium channel opener is chosen from 1-cyano-2-(1,1-dimethyl-propyl)-3-(3-pyridyl)guanidine and 5-alpha-reductase inhibitors.
17. (Original) A composition as claimed in claim 16, wherein at least one 5-alpha-reductase inhibitor is N-tert-butyl-3-oxo-4aza-5 α -androst-1-ene-17 β -carboxamide.
18. (Original) A composition as claimed in claim 11, wherein at least one hair growth-promoting compound is chosen from inner salts of 2,4-diamino-6-alkoxy-3-sulfoxypyrimidine hydroxide having from 1 to 6 carbon atoms in the alkoxy radical, pyridine 1-oxide compounds, and 2,6-diamino-1,3,5-triazine compounds.
19. (Original) A composition as claimed in claim 18, wherein at least one hair growth-promoting compound is an inner salt of 2,4-diamino-6-butoxy-3-sulfoxypyrimidine hydroxide.
20. (Original) A composition as claimed in claim 18, wherein at least one pyridine 1-oxide compound is 2,6-diamino-4-piperidinopyridine.
21. (Original) A composition as claimed in claim 18, wherein at least one 2,6-diamino-1,3,5-triazine compound is 2,6-diamino-4-butoxy-1,3,5-triazine 1-oxide.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

22. (Currently amended) A process for making a product for treatment of androgenic alopecia, comprising the step of forming said product by bringing together:

- a) at least one physiologically tolerated film-forming agent;
- b) at least one physiologically tolerated solvent;
- c) at least one plasticizer; and
- d) a compound of the formula I



or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

- R¹ is
- 1) -CN,
 - 2) -NO₂,
 - 3) a halogen, or
 - 4) (C₁-C₄)-alkyl-C(O)-OH;


- R² is
- 1) -CF₃,
 - 2) a halogen, or
 - 3) -CN;

- R³ is
- 1) =O,
 - 2) =S, or
 - 3) =NH;

- X is
- 1) a radical of formula II


FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com




or

2) a radical of formula III



or X and Y together form a group of formula IV



in which R⁴ is 1) hydrogen atom,

2) (C₁-C₆)-alkyl-,

3) (C₂-C₆)-alkenyl-, or

4) (C₁-C₆)-alkyl-,

wherein the alkyl is mono- to trisubstituted by

4.1 -OH,

4.2 halogens,

4.3 -O-(C₁-C₄)-alkyl,


4.4 -CN, or

4.5 -SH;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Y is 1) a radical of formula V




in which:

R^5 is, independently of R^6 , a hydrogen atom or $(\text{C}_1\text{-C}_4)$ -alkyl, wherein the alkyl is unsubstituted or mono- to tetrasubstituted by halogens, and R^6 is, independently of R^5 , $(\text{C}_1\text{-C}_4)$ -alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by

- a) halogens,
- b) phenyl- $(\text{CH}_2)_m$, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by -COOH, -CN, or -CF₃, and m is the integer zero, 1, 2, 3, 4, 5, or 6,
- c) -COOH,
- d) -CN, or
- e) -CF₃, or

2) a radical of formula VI,




FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

in which R⁴ is as defined above; and


- Z is 1) -O- or
- 2) a radical of formula VII



wherein said compound of formula I is released from the film formed by application of said composition to a skin surface.

23. (Currently amended) A process for making a product intended for treatment of seborrhea or acne, comprising the step of forming said product by bringing together:

- a) at least one physiologically tolerated film-forming agent;
- b) at least one physiologically tolerated solvent;
- c) at least one plasticizer; and
- d) a compound of the formula I



or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

- R¹ is 1) -CN,

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

- 2) $-\text{NO}_2$,
- 3) a halogen, or
- 4) $(\text{C}_1\text{-C}_4)\text{-alkyl-C(O)-OH}$;

R^2 is

- 1) $-\text{CF}_3$,
- 2) a halogen, or
- 3) $-\text{CN}$;

R^3 is

- 1) $=\text{O}$,
- 2) $=\text{S}$, or
- 3) $=\text{NH}$;


X is

- 1) a radical of formula II



or


- 2) a radical of formula III



or X and Y together form a group of formula IV

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com




- in which R⁴ is
- 1) hydrogen atom,
 - 2) (C₁-C₆)-alkyl-,
 - 3) (C₂-C₆)-alkenyl-, or
 - 4) (C₁-C₆)-alkyl-,

wherein the alkyl is mono- to trisubstituted by

- 4.1 -OH,
- 4.2 halogens,
- 4.3 -O-(C₁-C₄)-alkyl,
- 4.4 -CN, or
- 4.5 -SH;

- Y is 1) a radical of formula V



in which:


FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

R^5 is, independently of R^6 , a hydrogen atom or (C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono- to tetrasubstituted by halogens, and R^6 is, independently of R^5 , (C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by

- a) halogens,
- b) phenyl-(CH₂)_m-, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by -COOH, -CN, or -CF₃, and m is the integer zero, 1, 2, 3, 4, 5, or 6,
- c) -COOH,
- d) -CN, or
- e) -CF₃, or

2) radical of formula VI,




in which R^4 is as defined above; and

- Z is
- 1) -O- or
 - 2) a radical of formula VII

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com




wherein said compound of formula I is released from the film formed by application of said composition to a skin surface.

24-27. (Cancelled)

28. (Currently amended) A process for treatment of seborrhea or acne, comprising the step of applying to a patient in need or desire thereof a composition comprising:

- a) at least one physiologically tolerated film-forming agent;
- b) at least one physiologically tolerated solvent;
- c) at least one plasticizer; and
- d) a compound of the formula I



or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

- R¹ is
- 1) -CN,
 - 2) -NO₂,
 - 3) a halogen, or
 - 4) (C₁-C₄)-alkyl-C(O)-OH;

- R² is
- 1) -CF₃,
 - 2) a halogen, or
 - 3) -CN;


- R³ is
- 1) =O,
 - 2) =S, or
 - 3) =NH;

- X is
- 1) a radical of formula II



or

- 2) a radical of formula III




C1
cont'd

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER ^{LLP}

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

or X and Y together form a group of formula IV




- in which R⁴ is
- 1) hydrogen atom,
 - 2) (C₁-C₆)-alkyl-,
 - 3) (C₂-C₆)-alkenyl-, or
 - 4) (C₁-C₆)-alkyl-,

wherein the alkyl is mono- to trisubstituted by

- 4.1 -OH,
- 4.2 halogens,
- 4.3 -O-(C₁-C₄)-alkyl,
- 4.4 -CN, or
- 4.5 -SH;

- Y is 1) a radical of formula V



in which:


FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

R^5 is, independently of R^6 , a hydrogen atom or (C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono- to tetrasubstituted by halogens, and R^6 is, independently of R^5 , (C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by

- a) halogens,
- b) phenyl-(CH₂)_m-, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by -COOH, -CN, or -CF₃, and m is the integer zero, 1, 2, 3, 4, 5, or 6,
- c) -COOH,
- d) -CN, or
- e) -CF₃, or

2) radical of formula VI,




in which R^4 is as defined above; and

- Z is
- 1) -O- or
 - 2) a radical of formula VII

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP


1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com



wherein said compound of formula I is released from the film formed by application of said composition to a skin surface.

29. (Currently amended) A cosmetic composition comprising:

- a) at least one physiologically tolerated film-forming agent;
- b) at least one physiologically tolerated solvent;
- c) at least one plasticizer; and
- d) a compound of the formula I



or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

- R¹ is
- 1) -CN,
 - 2) -NO₂,
 - 3) a halogen, or
 - 4) (C₁-C₄)-alkyl-C(O)-OH;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER ^{LLP}

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

- R^2 is
- 1) $-CF_3$,
 - 2) a halogen, or
 - 3) $-CN$;


- R^3 is
- 1) $=O$,
 - 2) $=S$, or
 - 3) $=NH$;

- X is
- 1) a radical of formula II




or

- 2) a radical of formula III



or X and Y together form a group of formula IV



- in which R^4 is
- 1) hydrogen atom,

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER ^{LLP}


1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

- 2) (C₁-C₆)-alkyl-,
3) (C₂-C₆)-alkenyl-, or
4) (C₁-C₆)-alkyl-,

wherein the alkyl is mono- to trisubstituted by

- 4.1 -OH,
4.2 halogens,
4.3 -O-(C₁-C₄)-alkyl,
4.4 -CN, or
4.5 -SH;

Y is 1) a radical of formula V



in which:


R⁵ is, independently of R⁶, a hydrogen atom or (C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono- to tetrasubstituted by halogens, and
R⁶ is, independently of R⁵, (C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

- a) halogens,
- b) phenyl-(CH₂)_m-, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by -COOH, -CN, or -CF₃, and m is the integer zero, 1, 2, 3, 4, 5, or 6,
- c) -COOH,
- d) -CN, or
- e) -CF₃, or


- 2) a radical of formula VI,



in which R⁴ is as defined above; and

- Z is 1) -O- or

- 2) a radical of formula VII




wherein said compound of formula I is released from the film formed by application of said composition to a skin surface.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

30. (New) A method of treating skin substantially without hair cover comprising the step of applying to said skin of a patient in need or desire thereof a composition comprising:

- a) at least one physiologically tolerated film-forming agent;
- b) at least one physiologically tolerated solvent;
- c) at least one plasticizer; and
- d) a compound of the formula I



or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

- R¹ is
- 1) -CN,
 - 2) -NO₂,
 - 3) a halogen, or
 - 4) (C₁-C₄)-alkyl-C(O)-OH;

- R² is
- 1) -CF₃,
 - 2) a halogen, or

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

3) -CN;

R³ is


1) =O,

2) =S, or

3) =NH;


X is

1) a radical of formula II




or

2) a radical of formula III



or X and Y together form a group of formula IV



in which R⁴ is

1) hydrogen atom,

2) (C₁-C₆)-alkyl-,

3) (C₂-C₆)-alkenyl-, or

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

4) (C₁-C₆)-alkyl-,

wherein the alkyl is mono- to trisubstituted by

4.1 -OH,


4.2 halogens,

4.3 -O-(C₁-C₄)-alkyl,

4.4 -CN, or

4.5 -SH;

Y is 1) a radical of formula V



in which:

R⁵ is, independently of R⁶, a hydrogen atom or (C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono- to tetrasubstituted by halogens, and R⁶ is, independently of R⁵, (C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by

- a) halogens,
- b) phenyl-(CH₂)_m-, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com


-COOH, -CN, or -CF₃, and m is the integer zero, 1, 2, 3, 4, 5,
or 6,

c) -COOH,

d) -CN, or

e) -CF₃, or


2) radical of formula VI,



in which R⁴ is as defined above; and

Z is 1) -O- or

2) a radical of formula VII



wherein said compound of formula I is released from the film formed by application of
said composition to a skin surface.

31. (New) A method of treating skin substantially without hair cover as claimed in
claim 30, wherein the compound of formula I is a compound in which:

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

R¹ is 1) -CN,

2) -NO₂, or

3) a halogen;

R² is 1) -CF₃ or

2) a halogen;

R³ is 1) =O or

2) =S;

X is the radical of formula II or III, or

X and Y together form the group of formula IV,

in which R⁴ is as defined in claim 1;

Y is the radical of formula VI,

in which R⁴ is as defined in claim 1; and

Z is the radical of formula VII.

32. (New) A method of treating skin substantially without hair cover as claimed in claim 30, wherein the compound of formula I is a compound in which:

R¹ is -CN;

C1
cont'd

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

R² is -CF₃;

R³ is =0;

X is the radical of formula II;

Y is the radical of formula VI, in which R⁴ is hydrogen; and

Z is -O- or the radical of formula VII.

C
cont'd

33. (New) A method of treating skin substantially without hair cover as claimed in claim 30, wherein the compound of formula I is chosen from 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)benzonitrile and 4-(5-methyl-2,4-dioxo-5-trifluoromethyl)-oxazolidin-3-yl)-2-(trifluoromethyl)-benzonitrile.

34. (New) The method of treating skin substantially without hair cover as claimed in claim 30, wherein the composition further comprises at least one additive chosen from circulation-promoting compounds, angiotensin converting enzyme inhibitors, methylxanthine compounds, sodium channel openers, and hair growth-promoting compounds.

35. (New) The method of treating skin substantially without hair cover as claimed in claim 34, wherein at least one hair growth-promoting compound is chosen from inner salts of 2,4-diamino-6-alkoxy-3-sulfoxypyrimidine hydroxide having from 1 to 6 carbon

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

atoms in the alkoxy radical, pyridine 1-oxide compounds, and 2,6-diamino-1,3,5-triazine compounds.

36. (New) The method of treating skin substantially without hair cover as claimed in claim 35, wherein at least one hair growth-promoting compound is an inner salt of 2,4-diamino-6-butoxy-3-sulfoxypyrimidine hydroxide.

37. (New) The method of treating skin substantially without hair cover as claimed in claim 35, wherein at least one pyridine 1-oxide compound is 2,6-diamino-4-piperidinopyridine.

38. (New) The method of treating skin substantially without hair cover as claimed in claim 35, wherein at least one 2,6-diamino-1,3,5-triazine compound is 2,6-diamino-4-butoxy-1,3,5-triazine 1-oxide.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER ^{LLP}

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com